# Advancements in Precision Cancer Medicine: Integrating Artificial Intelligence with Metabolomics for Enhanced Diagnostic and Prognostic Accuracy

**Sujimon Mungkalarungsi[1*], Nattaka Limranangkula[2], Pichayapa Yuphong[3], Mantana Kongtanakusul[4], Sooknapat Chongsawadvorakul[5], Somprat Suratannon[6], Punchaya Tapaneeyasathid[7], and Phatthicha Leowattana[8]**

## ABSTRACT

Cancer is a complex disease that requires continued research and advancements in prevention and treatment. Understanding the metabolic alterations that occur in cancer cells is essential for developing precision cancer medicine. Metabolomics has emerged as a powerful tool for studying cancer metabolism. By profiling the metabolite composition of a cancer, metabolomics enables the identification of metabolic signatures associated with specific cancer types and stages, as well as the discovery of novel biomarkers for diagnosis and prognosis. By combining artificial intelligence with metabolomics, scientists can reveal perspectives on cancer biology, leading to tailored therapeutic strategies.

---

[1*] Independent researcher
[2] International Community School
[3] Satriwithaya School
[4] Assumption College Thonburi
[5] Patumwan Demonstration School
[6] Triam Udom Suksa School
[7] Assumption Convent School
[8] Denla British School
[*] Corresponding author e-mail: khunsujimon.m@gmail.com
Received: Aug 10, 2024 Revised: Nov 28, 2024 Accepted: Dec 20, 2024

This article provides a comprehensive review of the integration of artificial intelligence and metabolomics in precision cancer medicine approaches.

Keywords: Metabolomics, biomarker, cancer, Artificial Intelligence, Precision Medicine

## Introduction

Cancer is a complex disease marked by uncontrolled cell growth and the potential for metastasis, contributing significantly to global health challenges (Clish, 2015). Rising incidence and mortality rates emphasize the urgency for continued advancements in prevention, early detection, and treatment. Cancer subtyping through molecular characteristics is essential for individualized therapy and understanding cancer heterogeneity, yet challenges in classification have limited its broad clinical application. Effective cancer subtyping enables tailored therapy selection and precision medicine approaches that significantly enhance patient outcomes (Tsimberidou, Fountzilas, Nikanjam, & Kurzrock, 2020).

Metabolomics has emerged as a pivotal field for studying cancer metabolism by enabling comprehensive profiling of metabolites—small molecule signatures that reflect the molecular phenotype of cancer cells (Ngan, Lam, Li, Zhang, & Cai, 2023). By examining metabolic alterations in tumors, metabolomics provides valuable insights for biomarker discovery and disease characterization across cancer types (Liberti & Locasale, 2016). However, limitations in sample interpretation, particularly when comparing biofluids (e.g., blood, urine) to tissue samples, affect data consistency and the interpretation of biomarkers for diagnostic and prognostic applications (German, Hammock, & Watkins, 2005; Danzi et al., 2023).

AI integration into cancer metabolomics is revolutionizing diagnostic accuracy and treatment precision. Although still developing, studies show that AI can improve cancer diagnostics by identifying intricate metabolic patterns in large datasets (Barberis et al., 2022). Nevertheless, only a few studies have fully examined the role of AI in enhancing cancer diagnostics and treatment efficacy. To address this gap, this review evaluates current research on AI in cancer metabolomics, discusses the relevance of

specific biomarker samples, and presents a comprehensive table summarizing biomarkers identified across cancer types. (Table 1)

**Table 1:** Identified Biomarkers by Cancer Type

| No. | Cancer Type | Biomarker | Sample Type | Metabolomic Method | Diagnostic/Prognostic Significance | Key References |
|---|---|---|---|---|---|---|
| 1 | Lung Cancer | Polyamines | Plasma | LC-MS | Predictive of Chemotherapy Response | Klupczynska et al. (2017) |
| 2 | Lung Cancer | Lactate | Serum | LC-MS | Associates with Cancer Progression | Peng et al. (2018) |
| 3 | Renal Cell Carcinoma (RCC) | Amino Acids | Urine | LC-MS | Diagnostic Potential | Bifarin et al. (2021) |
| 4 | Ovarian Cancer | Lipids | Serum | UPLC-MS/MS | Associated with Cancer-Specific Metabolic Shifts | Gaul et al. (2015) |
| 5 | Prostate Cancer | Glucose Derivatives | Tissue | LC-MS | Biomarker for Cancer Subtyping | Ren S. et al. (2016) |
| 6 | Breast Cancer | Fatty Acids | Serum | GC-MS | Provides Comprehensive Metabolic Insights | Hassan et al. (2020) |

In summary, this article explores the integration of AI and metabolomics in precision oncology, providing foundational insights into metabolic shifts across cancer types. By clarifying the roles of sample types, reviewing AI contributions to diagnostic improvements, and presenting a detailed summary of biomarkers, this work advances understanding in AI-assisted cancer metabolomics.

## Study Methods

This review assesses the integration of AI and metabolomics in precision cancer medicine through:

1. Literature Review: Systematic collection of studies on AI applications in metabolomics, biomarker discovery, and cancer diagnostics to examine advancements across major cancer types and evaluate biomarker impacts on prognosis and treatment.

2. Metabolomic Techniques Analysis: Examination of studies using NMR, MS, and chromatography techniques to assess effectiveness in biomarker detection and relevance across biofluid and tissue samples.

3. AI Methodologies Evaluation: Analysis of AI algorithms (e.g., machine learning, deep learning) in data processing and cancer subtype classification, focusing on predictive modeling and integration with other omics data.

4. Cancer-specific Findings: Review of studies on lung, breast, prostate, RCC, and ovarian cancer to summarize metabolic and biomarker characteristics and AI-driven improvements in diagnostics and care.

5. Biomarker Table Compilation: Creation of a table categorizing key biomarkers by cancer type, diagnostic relevance, and sample type, providing a structured overview for precision oncology.

This synthesis highlights AI-enhanced metabolomics' impact on cancer diagnosis, treatment precision, and prognosis, advancing precision cancer medicine. (Table 2)

**Table 2:** AI-Enhanced Precision Medicine Approaches In Metabolomics

| No. | AI Approach | Application in Cancer Type | Outcome/Benefit | Limitations | Key Studies |
|---|---|---|---|---|---|
| 1 | Machine Learning | Breast Cancer | Predictive Modeling for Treatment Response | Data Integration Challenges | Irajizad et al. (2022) |
| 2 | Deep Learning | Pancreatic Cancer | Enhanced Biomarker Detection and Outcome Prediction | Ethical and Data Handling Limitations | Katta et al. (2023) |
| 3 | AutoML-XAI | Renal Cell Carcinoma | Distinguishes RCC from Other Types | Limited Clinical Integration | Bifarin & Fernandez (2023) |
| 4 | Radiomics Integration | Various Types | Improves Diagnostic Accuracy in Imaging | High Computational Requirements | Mbodi, Mathebela, & Dlamini (2023) |
| 5 | Predictive Modeling | Lung Cancer | Predicts Chemotherapy Efficacy | Statistical and Sample Size Limitations | Peng et al. (2018) |

## METABOLOMICS

Metabolomics, a branch of systems biology, is dedicated to the comprehensive study of endogenous small molecules, or metabolites, within biological systems. This approach aims to quantify metabolic biomarkers associated with cancer detection and treatment efficacy, with initial discovery typically occurring in preclinical settings using animal models and human cell cultures. These biomarkers then undergo translational validation in patient-derived biofluids (e.g., blood, urine) or tumor tissues to assess clinical relevance. Biofluids and tissue samples offer distinct advantages for noninvasive and targeted biomarker validation, respectively, depending on the origin and type of cancer (Ngan et al., 2023).

Metabolomic analyses commonly rely on advanced technologies like nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), both of which enable precise detection and quantification of metabolites. MS-based metabolomics, in particular, employs separation techniques—such as gas chromatography (GC) and liquid chromatography (LC)—to handle complex biological mixtures before analysis, enhancing the specificity and sensitivity of biomarker detection (Petrick & Shomron, 2022). This separation process simplifies complex spectra, improves isobaric differentiation, and provides additional physicochemical details about metabolites.

While mass spectrometry-based techniques are powerful, they often require specific sample preparation that can result in metabolite loss. Depending on the sample introduction and ionization methods used, certain metabolite classes may be excluded, making it essential to use complementary techniques (e.g., GC-MS and LC-MS) for a more comprehensive view of the metabolome. Metabolomics, as the closest "omics" field to phenotype, captures the direct metabolic responses to cellular and environmental stimuli, offering high-throughput and dynamic profiling of metabolites (German et al., 2005). The field continues to grow, with MS-based approaches expanding rapidly in publications compared to NMR-based studies (Dettmer et al., 2007), underscoring its impact on cancer research and biomarker discovery.

## CANCER METABOLOMICS

Cancer metabolism is fundamentally reprogrammed within tumor cells to meet the heightened demands for energy, biosynthesis, and survival, often driven by the Warburg Effect—wherein cells favor glycolysis over oxidative phosphorylation even in oxygen-rich conditions (Liberti & Locasale, 2016). This metabolic rewiring includes increased nutrient uptake, alterations in nitrogen metabolism, and shifts in gene expression, collectively fostering tumor growth and progression (Danzi et al., 2023; Martínez-Reyes & Chandel, 2021). Metabolomics has become an invaluable tool for analyzing these small-molecule metabolites, aiding in biomarker discovery and uncovering the metabolic signatures associated with different stages and types of cancer (Han, Li, Chen, & Yang,  et al., 2021; Schmidt et al., 2021). By integrating metabolomics with other omics approaches, researchers are identifying metabolic

vulnerabilities in cancer cells, which holds promise for advancing personalized medicine and improving treatment strategies (Huang et al., 2022).

**Key Studies in Cancer-specific Metabolomics**

**1. Lung Cancer**

Recent studies highlight specific metabolomic biomarkers in lung cancer. Klupczynska et al. (2017) identified 12 biomarkers in serum using LC-MS, linking these markers to physiological processes associated with lung cancer. Peng et al. (2018) further identified eight biomarkers predictive of chemotherapy response, using plasma samples and LC-MS analysis. Ruiying et al. (2020) and Xie et al. (2021) corroborated these findings, each identifying additional metabolic markers linked to lung cancer progression and treatment response, reinforcing the potential of metabolomics for tailored lung cancer therapies.

**2. Renal Cell Carcinoma (RCC)**

In RCC research, Jing et al. (2019) identified 21 tissue biomarkers using LC-MS, which correlated strongly with RCC pathology. Bifarin et al. (2021) expanded this understanding by identifying 10 urine biomarkers for RCC, highlighting noninvasive diagnostic potential. McClain et al. (2022) used serum samples to identify six additional biomarkers, advancing RCC diagnostic and therapeutic possibilities through metabolomic profiling.

**3. Ovarian Cancer**

Gaul et al. (2015) employed UPLC-MS/MS to identify 16 serum biomarkers associated with ovarian cancer, offering insights into disease-specific metabolic shifts. Buas et al. (2016) further identified 34 plasma biomarkers, linking 17 of these with significant correlations to ovarian cancer pathology, which can serve as valuable diagnostic and prognostic markers for the disease.

**4. Prostate Cancer**

Ren S. et al. (2016) analyzed tissue samples via LC-MS, uncovering 27 biomarkers specifically associated with prostate cancer's metabolic landscape. In parallel, Kumar, Gupta, Mandhani, & Sankhwar (2016) used NMR spectroscopy on serum samples to identify 52 additional biomarkers, broadening the scope of prostate cancer diagnostics and paving the way for refined therapeutic options.

**5. Breast Cancer**

Kanaan et al. (2014) used GC-MS and LC-MS on tissue samples, identifying 133 biomarkers that provide comprehensive metabolic insights into breast cancer. Hassan et al. (2020) focused on serum samples, uncovering 96 additional biomarkers using LC-MS. These studies collectively highlight metabolomics' role in diagnosing, subtyping, and prognosticating breast cancer, supporting precision oncology.

**Implications for Personalized Cancer Medicine**

Metabolomics offers powerful insights into cancer metabolism, enabling the detection of cancer-specific biomarkers that reflect tumor metabolism's dynamic nature. By studying metabolic pathways unique to each cancer type, metabolomics facilitates the development of personalized treatment strategies and enhances our understanding of cancer progression. The field's integration with AI-driven analysis has further expanded its potential in identifying subtle patterns within metabolomic data, bolstering the accuracy and effectiveness of cancer diagnostics and treatments.

## AI-ASSISTED CANCER METABOLOMICS

The complexity of metabolomics data, characterized by both nonlinear and linear correlations among metabolites, presents analytical challenges that require sophisticated algorithms to derive meaningful biological insights. Challenges in data analysis, such as missing values, batch effects, data noise, and issues with reproducibility, make AI an invaluable tool in metabolomics, especially in the context of cancer research (Barberis et al., 2022). By employing AI, researchers can efficiently process high-dimensional metabolomics data, identify patterns, and link metabolites to known biochemical pathways in public databases, allowing for a deeper understanding of the metabolic landscape in cancer.

**AI's role in metabolomics spans three major levels:**

- Primary Data Processing: Standardizing raw data and converting it into analyzable formats.

- Bioinformatic Analysis: Predictive modeling and classification of cancer types or subtypes based on metabolomic profiles.

- Integration with Other Omics: Merging metabolomics with transcriptomics, proteomics, and microbiome data for a holistic view of cancer biology.

These advancements, along with single-cell analysis technologies, allow researchers to investigate cancer metabolism at cellular resolution, enabling detailed quantitative studies of complex and heterogeneous tumor profiles (Danzi et al., 2023).

AI applications in cancer metabolomics are advancing diagnostic and therapeutic precision in oncology. Irajizad et al. (2022) demonstrated that AI-assisted analysis of plasma polyamines and related metabolites could predict response to neoadjuvant chemotherapy (NACT) in breast cancer, where elevated pre-treatment levels of acetylated polyamines correlated with higher tumor burden post-NACT. This AI-driven approach identified metabolite panels capable of predicting poor NACT response, potentially guiding alternative treatment choices for those unlikely to benefit from standard therapy.

In renal cell carcinoma (RCC) and ovarian cancer diagnostics, AI-optimized metabolomics analysis has enabled the differentiation of RCC from healthy controls and the distinction between ovarian and other gynecological cancers (Bifarin & Fernández, 2023). Similarly, Katta et al. (2023) explored AI's use in pancreatic cancer, noting its ability to enhance biomarker detection, improve diagnostic accuracy, and predict treatment outcomes. However, challenges such as statistical limitations, data handling issues, ethical considerations, and integration into clinical settings still require attention for widespread AI adoption in clinical oncology.

The combined power of AI and metabolomics is particularly evident in precision oncology, where applications like radiogenomics enhance cancer diagnosis, treatment planning, and prognosis assessment. As advancements in next-generation sequencing improve tumor classification through circulating tumor DNA (ctDNA) and copy number variation analyses, AI further aids by reducing the need for invasive histological methods. Integrating radiomics and deep learning into diagnostic imaging workflows also promises greater accuracy in image analysis, ultimately enhancing disease management and patient care in oncology (Mbodi et al., 2023).

## PRECISION CANCER MEDICINE APPROACHES

Precision medicine in oncology aims to identify specific patient biomarkers that are critical for selecting the most effective treatments. Biomarkers, which can be single data points or composite measurements derived from various sources, serve several roles. They may be **prognostic**, indicating a patient's general disease outlook; **predictive**, helping to forecast treatment response across therapies; or **prescriptive**, guiding specific treatment choices to optimize patient outcomes (Tsimberidou et al., 2020). Evidence increasingly shows that matched therapies, which align treatments with patients' unique biomarker profiles, yield better outcomes than non-matched therapies across a variety of cancers. For maximum benefit, precision medicine should be implemented early in a patient's disease course, ideally following comprehensive tumor profiling and with access to effective, targeted therapies.

Metabolomics, the latest addition to omics technologies, leverages advanced analytical and pattern recognition tools to detect metabolic changes that signal disease status or responses to treatments. Cancer cells rely heavily on altered metabolic pathways, such as those involving glucose and glutamate, to fuel their growth and proliferation. These pathways are also essential for synthesizing biomolecules like carbohydrates, fatty acids, and nucleotides, which are vital for cancer cell survival. By targeting these altered pathways, precision medicine therapies can disrupt cancer cell metabolism. For instance, drugs may be developed to:

- **Inhibit enzymes** that drive unchecked cancer cell growth and survival,
- **Block aberrant gene expression** characteristic of cancer cells, or
- **Halt hyperactive signaling pathways** that promote tumor development.

Targeted therapies in precision medicine focus specifically on features unique to cancer cells, minimizing the risk of harming normal cells compared to conventional treatments like chemotherapy and radiation. However, barriers remain in making these treatments widely accessible. Access to the latest precision medicine advancements can be limited by geography, healthcare infrastructure, and the availability of clinical trials. Many precision medicine trials are offered only at larger cancer centers, which restricts participation opportunities for patients in remote or underserved areas.

Furthermore, outside of clinical trials, precision medicine applications may still be underutilized due to logistical or financial constraints.

To expand the reach and efficacy of precision cancer medicine, researchers are actively addressing these limitations through ongoing laboratory studies and clinical trials. Efforts are underway to make precision oncology more accessible and effective, with the ultimate goal of integrating personalized approaches seamlessly into standard cancer care.

## Discussion

Cancer metabolomics offers significant advantages for diagnostics, enabling detection of cancer-specific metabolic profiles and early biomarkers. Its noninvasive sampling and sensitivity in detecting metabolic shifts allow for more personalized and accurate diagnostics. However, limitations persist due to sample variability (e.g., biofluid vs. tissue) and influences from external factors, which can complicate biomarker interpretation. Additionally, high costs and technical requirements can limit widespread clinical adoption.

AI enhances metabolomics by processing complex datasets, detecting patterns, and integrating metabolomic data with other omics layers, improving diagnostic precision and biomarker discovery. It also addresses data variability through standardization. Despite these advantages, AI has limitations, including the need for large, high-quality datasets, computational resources, and challenges with model interpretability, which can hinder clinical trust and adoption.

While AI-assisted metabolomics holds great potential for advancing cancer diagnostics, addressing challenges in data quality, sample variability, and AI transparency is essential for its broader clinical integration and impact in precision oncology.

## Conclusion

Precision medicine, metabolomics, and AI-driven approaches are reshaping cancer diagnosis, prognosis, and treatment. Metabolomics has proven crucial in identifying cancer-specific biomarkers, while AI enhances this process by analyzing complex data patterns to improve diagnostic accuracy. Together, these tools enable more personalized and effective cancer therapies with fewer side effects.

However, challenges remain, including data management, ethical issues, and limited access to advanced treatments. Expanding precision medicine's reach through continued research and improved accessibility is vital to making cancer care more personalized, effective, and widely available.

## References

Barberis, E., Khoso, S., Sica, A., Falasca, M., Gennari, A., Dondero, F., Afantitis, A. & Manfredi, M. (2022). Precision Medicine Approaches with Metabolomics and Artificial Intelligence. **Int J Mol Sci**, 23(19), 11269.

Bifarin, O. O., & Fernández, F. M. (2023). Automated machine learning and explainable AI (AutoML-XAI) for metabolomics: improving cancer diagnostics. **bioRxiv: the preprint server for biology**, 2023.10.26.564244.

Bifarin, O. O., Gaul, D. A., Sah, S., Arnold, R. S., Ogan, K., Master, V. A., Roberts, D. L., Bergquist, S. H., Petros, J. A., Fernández, F. M., & Edison, A. S. (2021). Machine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics. **J Proteome Res**, 20(7), 3629-3641.

Buas, M. F., Gu, H., Djukovic, D., Zhu, J., Drescher, C. W., Urban, N., Raftery, D., & Li, C. I. (2016). Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. **Gynecol Oncol**, 140(1), 138-44.

Clish, C. B. (2015). Metabolomics: an emerging but powerful tool for precision medicine. **Cold Spring Harb Mol Case Stud**, 1(1), a000588.

Danzi, F., Pacchiana, R., Mafficini, A., Scupoli, M. T., Scarpa, A., Donadelli, M., & Fiore, A. (2023). To metabolomics and beyond: a technological portfolio to investigate cancer metabolism. **Signal Transduct Target Ther**, 8(1), 137.

Dettmer, K., Aronov, P. A., & Hammock, B. D. (2007). Mass spectrometry-based metabolomics. **Mass Spectrom Rev**, 26(1), 51-78.

Gaul, D. A., Mezencev, R., Long, T. Q., Jones, C. M., Benigno, B. B., Gray, A., Fernández, F. M., & McDonald, J. F. (2015). Highly-accurate metabolomic detection of early-stage ovarian cancer. **Sci Rep**, 5, 16351.

German, J. B., Hammock, B. D., & Watkins, S. M. (2005). Metabolomics: building on a century of biochemistry to guide human health. **Metabolomics**, 1, 3–9.

Han, J., Li, Q., Chen, Y., & Yang, Y. (2021). Recent metabolomics analysis in tumor metabolism reprogramming. Front Mol. **Biosci**, 8, 763902.

Hassan, M. A., Al-Sakkaf, K., Shait Mohammed, M. R., Dallol, A., Al-Maghrabi, J., Aldahlawi, A., Ashoor, S., Maamra, M., Ragoussis, J., Wu, W., Khan, M. I., Al-Malki, A. L., & Choudhry, H. (2020). Integration of Transcriptome and Metabolome Provides Unique Insights to Pathways Associated with Obese Breast Cancer Patients. **Front Oncol**, 10, 804.

Huang, J., Zhao, B., Weinstein, S. J., Albanes, D., & Mondul, A. M. (2022). Metabolomic profile of prostate cancer-specific survival among 1812 Finnish men. **BMC Med**, 20, 362.

Irajizad E, Wu, R., Vykoukal, J., Murage, E., Spencer, R., Dennison, J. B., Moulder, S., Ravenberg, E., Lim, B., Litton, J., Tripathym, D., Valero, V., Damodaran, S., Rauch, G. M., Adrada, B., Candelaria, R., White, J. B., Brewster, A., Arun, B., Long, J. P., Do, K. A., Hanash, S., & Fahrmann, J. F. (2022). Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. **Front ArtifIntell**, 5, 876100.

Jing, L., Guigonis, J. M., Borchiellini, D., Durand, M., Pourcher, T., & Ambrosetti, D. (2019). LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes. **Sci Rep**, 9(1), 15635.

Kanaan, Y. M., Sampey, B. P., Beyene, D., Esnakula, A. K., Naab, T. J., Ricks-Santi, L. J., Dasi, S., Day, A., Blackman, K. W., Frederick, W., Copeland, R. L., Sr., Gabrielson, E., & Dewitty, R.L., Jr. (2014). Metabolic profile of triple-negative breast cancer in African-American women reveal potential biomarkers of aggressive disease. **Cancer Genomics Proteomics**, 11(6), 279-94.

Katta, M. R., Kalluru, P. K. R., Bavishi, D. A., Hameed, M., & Valisekka, S. S. (2023). Artificial intelligence in pancreatic cancer: diagnosis, limitations, and the future prospects-a narrative review. **J Cancer Res Clin Oncol**, 149(9), 6743-6751.

Klupczynska, A., Derezinski, P., Garrett, T. J., Rubio, V. Y., Dyszkiewicz, W., Kasprzyk, M., & Kokot, Z. J. (2017). Study of early stage non-small-cell lung cancer using Orbitrap-based global serum metabolomics. **J Cancer Res Clin Oncol**, 143(4), 649-659.

Kumar, D., Gupta, A., Mandhani, A., & Sankhwar, S.N. (2016). NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics. **Prostate**, 76(12), 1106-19.

Liberti, M. V., & Locasale, J. W. (2016). The Warburg Effect: How Does it Benefit Cancer Cells? **Trends Biochem Sci**, 41(3), 211-218.

Martínez-Reyes, I., & Chandel, N. S. (2021). Cancer metabolism: looking forward. **Nat Rev Cancer**, 21(10), 669-680.

McClain, K. M., Sampson, J. N., Petrick, J. L., Mazzilli, K. M., Gerszten, R. E., Clish, C. B., Purdue, M. P., Lipworth, L., & Moore, S. C. (2022). Metabolomic Analysis of Renal Cell Carcinoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. **Metabolites**, 12(12), 1189.

Mbodi, L., Mathebela, P., & Dlamini, Z. (2023). Association of Metabolomics with AI in Precision Oncology: Emerging Perspectives for More Effective Cancer Care. **Artificial Intelligence and Precision Oncology**, 139-156.

Ngan, H. L., Lam, K. Y., Li, Z. C., Zhang, J. L., & Cai, Z. W. (2023). Machine learning facilitates the application of mass spectrometry-based metabolomics to clinical analysis: A review of early diagnosis of high mortality rate cancers. **Trends Anal. Chem**, 168, 117333.

Peng, F., Liu, Y., He, C., Kong, Y., Ouyang, Q., Xie, X., Liu, T., Liu, Z., & Peng, J. (2018). Prediction of platinum-based chemotherapy efficacy in lung cancer based on LC-MS metabolomics approach. **J Pharm Biomed Anal**, 154, 95-101.

Petrick, L. M., & Shomron, N. (2022). AI/ML-driven advances in untargeted metabolomics and exposomics for biomedical applications. **Cell Rep Phys Sci**, 3(7), 100978.

Ren, S., Shao, Y., Zhao, X., Hong, C. S., Wang, F., Lu, X., Li, J., Ye, G., Yan, M., Zhuang, Z., Xu, C., Xu, G., & Sun, Y. (2016). Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer. **Mol Cell Proteomics**, 15(1), 154-63.

Ruiying, C., Zeyun, L., Yongliang, Y., Zijia, Z., Ji, Z., Xin, T., & Xiaojian, Z. (2020). A comprehensive analysis of metabolomics and transcriptomics in non-small cell lung cancer. **PLoS One**, 15(5), e0232272.

Schmidt, D. R., Patel, R., Kirsch, D. G., Lewis, C. A., Vander Heiden, M. G., & Locasale, J. W. (2021). Metabolomics in cancer research and emerging applications in clinical oncology. **CA Cancer J Clin**, 71(4), 333-358.

Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020). Review of precision cancer medicine: Evolution of the treatment paradigm. **Cancer Treat Rev**, 86, 102019.

Xie, Y., Meng, W. Y., Li, R. Z., Wang, Y. W., Qian, X., Chan, C., Yu, Z. F., Fan, X. X., Pan, H. D., Xie, C., Wu, Q. B., Yan, P. Y., Liu, L., Tang, Y. J., Yao, X. J., Wang, M. F., & Leung, E. L. (2021). Early lung cancer diagnostic biomarker discovery by machine learning methods. **Transl Oncol**, 14(1), 100907.